ClinicalTrials.gg
TerminatedNCT00833287ObesityRoleUpdated Apr 6, 2012

Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity

An observational study in Trauma and Obesity, sponsored by University of Mississippi Medical Center. Terminated. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-04-06.

Sponsored by University of Mississippi Medical Center · Observational

Why this study was terminated
Enrollment process not efficient
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patient who have major traumatic injury are at risk to develop postoperative inflammatory complications such as pneumonia and lung trouble called adult respiratory distress syndrome (ARDS). This study will draw blood from trauma patients are several time points after their injury to see if we can predict who is at greatest risk for developing pneumonia or ARDS based upon the results of these immune lab tests. We are particularly interested to see if this will be useful in obese patients who have a greater risk of these post trauma complications

Read the detailed description

The role of inflammation in disease is increasingly appreciated in clinical medicine. Too much or too long a course of inflammation can lead to serious and sometime fatal complications for patients who experience significant physical trauma, particularly those whose injuries are serious enough to warrant intensive care follow up. On the other hand, the sheer stress of the traumatic injury can leave patients deficient in their ability to mount a protective immune/inflammatory response leaving them susceptible to concomitant infection. Another component to the conundrum is that after the trauma (first hit), the surgeons are faced with the dilemma of complete surgical repair of the injury - the second hit (i.e. full orthopedic repairs) vs stabilization of the injury until the patient recovers from the shock of the first hit. The difficulty for the medical team is predicting who can safely tolerate a full second hit (total surgical restoration) vs who needs to be further stabilized before further intervention. In the obese individual, this conundrum is compounded by the known immune/inflammatory alterations characteristic of the obese state. How these patients in particular can be safely triaged for immediate vs delayed definitive therapy based upon specific immune/inflammatory parameters is the object of this initial pilot study.

Hypothesis

Obese individuals who experience severe traumatic injury will develop immunoregulatory dysfunction shortly after injury that is greater than nonobese individuals experiencing similar traumatic injury. Depending upon severity and duration of this immunoregulatory dysfunction, the post injury inflammatory responses will also be altered resulting in increased risk for pneumonia and/or adult respiratory distress syndrome, major morbidities associated with trauma.

Specific Aims

  1. Determine immunoregulatory and inflammatory blood cytokine and endocrine stress hormone profiles in adult patients with significant traumatic injury correlated with subsequent development of pneumonia and/or adult respiratory distress syndrome.
  2. Examine the role of obesity in the initial immunoregulatory dysfunction and subsequent short term clinical course of trauma patients.
  3. Investigate whether demographic differences (age, gender, race) impact the risk for immunoregulatory and/or inflammatory dysfunction as well as risk for pneumonia and/or adult respiratory distress syndrome in obese s non obese trauma patients.
02

Conditions studied

  • Trauma
  • Obesity

Keywords

  • immunoregulatory
  • dysfunction
  • obesity
03

In context

Wounds and Injuries

5,085 studies on the registry are indexed under Wounds and Injuries; 849 are open to participants now.

This study's enrollment of 10 is below the median of 135 across 1,603 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

University of Mississippi Medical Center is the lead sponsor of 129 studies on the registry; 20 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patient with significant traumatic injury

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age 18 and older
  2. traumatic injury of sufficient severity that ICU care is anticipated
  3. Likely (by clinical criteria) to survive for at least 7 days after enrollment

Exclusion criteria

Exclusion Criteria:

  1. age less than 18 (not at risk for ARDS)
  2. minor trauma not requiring ICU monitoring
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (actual)
Biospecimen retention
Samples without dna
06

Study locations

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00833287
Responsible party
Sponsor
First posted
Feb 2, 2009
Start date
Nov 2008
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Apr 6, 2012

Study contacts

George V Russell, M.D.
principal investigator · University of Mississippi Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion